Below $1 billion • 25%

$1 billion to $1.5 billion • 25%

$1.5 billion to $2 billion • 25%

Above $2 billion • 25%

Less than $100 million • 25%

$100 million to $500 million • 25%

$500 million to $1 billion • 25%

Over $1 billion • 25%

Yes • 50%

No • 50%

Revenue increases by 10% or more • 25%

Revenue stays within 10% of current levels • 25%

Revenue decreases by 10% or more • 25%

Cassava Sciences reports a loss • 25%

Below $20 • 25%

$20 to $40 • 25%

$40 to $60 • 25%

Above $60 • 25%

Stock price above $50 • 25%

Stock price between $20 and $50 • 25%

Stock price between $5 and $20 • 25%

Stock price below $5 • 25%

Above $200 million • 25%

Between $100 million and $200 million • 25%

Between $50 million and $100 million • 25%

Below $50 million • 25%

Outperforms • 33%

Performs similarly • 34%

Underperforms • 33%

Announce a new drug development • 25%

Seek partnerships or mergers • 25%

Focus on non-Alzheimer's projects • 25%

Other strategic move • 25%

Yes • 50%

No • 50%

Favorable ruling for Cassava Sciences • 25%

Unfavorable ruling for Cassava Sciences • 25%

Settlement • 25%

Case dismissed • 25%

Yes • 50%

No • 50%